Latest News Archive

Please select Category, Year, and then Month to display items

Agreement between UFS rectorate and Institutional Student Representative Council (ISRC) on 16 March 2021

16 March 2021 | Story Lacea Loader

UPDATE: 16 March 2021 at 20:37

During a meeting between members of the Rectorate and representatives of the Institutional Student Representative Council (ISRC) on 15 and 16 March 2021, the following was agreed upon:

1. SUSPENSION OF THE ACADEMIC PROGRAMME

All academic activities have been suspended on all UFS campuses from 17 to 22 March 2021. No online/face-to-face lectures/tests/assignments will take place until 23 March 2021, and the full academic programme will resume on this date.

This decision will allow the university management an opportunity to address outstanding matters regarding the admission of senior undergraduate students.

2. FACE-TO-FACE REGISTRATION

Any senior undergraduate and first-year student who is unable to register successfully online, can do so on the Bloemfontein and Qwaqwa Campuses from 17 to 19 March 2021.

► Registration stations:

Bloemfontein Campus:

- Examination Centre (EXR)

Qwaqwa Campus:

- Faculty of Education: Mandela Hall
- Faculty of the Humanities: E0013 + 14
- Faculty of Economic and Management Sciences: E009 + 10 – EMS
- Faculty of Natural and Agricultural Sciences: Fulufhelo Gazelle

► Operating times on both campuses:

17 March 2021: 13:00-15:00
18 and 19 March 2021: 8:00-15:00

The following must be noted:

Senior undergraduate students must be in possession of a valid student card (previous year) and will be allowed to enter the campuses without an access permit in order to register.

First-year students must be in possession of a firm offer from the UFS in order to register – no campus access permit is needed.

3. NUMBER OF STUDENTS ON CAMPUSES

The university management is aware of the challenges that some students are experiencing with the continuation of their studies off campus in terms of, for instance, access to campus facilities and connectivity.

It is, however, important to take note that the institution is obliged to adhere to national regulations linked to Level 1 of the national lockdown, also taking into account the university’s teaching and learning approach, as well as the capacity to adhere to physical distancing protocols.

The university management will continue with the return of students to the campuses in a responsible way, as the safety, health, and well-being of students and staff remain the key priorities.

With this in mind, the university will reconsider its blended learning arrangements for 2021 to allow more students to return to campus within the parameters of the national lockdown regulations. These arrangements will be communicated to students soon.

4. ACADEMICALLY ELIGIBLE STUDENTS

The university will compile a list of students who have outstanding debt and who are still awaiting funding confirmation from NSFAS. Confirmation will be provided before midnight on 16 March 2021 if these students can register provisionally without payment of the first amount.

5. MEAL ALLOWANCES

The payment of meal allowances for NSFAS students will be implemented by the end of March 2021. It should be noted that NSFAS is only expected to transfer funds in April, but the UFS will lay out the funds for food allowances in the meantime.

6. ACADEMIC EXCLUSION

During the meetings on 15 and 16 March 2021, the ISRC tabled the matter regarding students who are academically excluded for the 2021 academic year. This matter is being addressed by the university management and engagement in this regard will continue.

7. VICTIMISATION OF STUDENTS BY PRIVATE SECURITY

During the meetings on 15 and 16 March 2021, the ISRC tabled the matter regarding students being victimised, harassed, and assaulted by private security.

The ISRC will submit more information, after which the allegations will be investigated.

Released by:
Lacea Loader (Director: Communication and Marketing)
Telephone: +27 51 401 2584 | +27 83 645 2454
Email: news@ufs.ac.za | loaderl@ufs.ac.za
Fax: +27 51 444 6393

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept